SGLT2 Inhibitor Ketosis Risk

Why Can SGLT2 Inhibitors Raise Ketosis Risk?

Sodium-glucose cotransporter-2 inhibitors, including empagliflozin, dapagliflozin and canagliflozin, help the kidneys remove glucose through urine. This mechanism is clinically valuable in type 2 diabetes and has become important in cardiovascular and kidney care, but it can also change the body's fuel balance, especially during insulin deficiency, fasting, dehydration, acute illness or reduced carbohydrate intake.

The key safety concern is diabetic ketoacidosis, including euglycemic diabetic ketoacidosis, where blood glucose may be lower than expected despite dangerous acid buildup. The American Diabetes Association notes that euglycemic DKA can occur with plasma glucose below 200 mg/dL, making symptoms and ketone testing especially important rather than relying on glucose readings alone.

What Did The Empagliflozin Metabolism Study Add?

The Nature portfolio journal Nutrition & Diabetes reported experimental work evaluating whether non-carbohydrate anaplerotic therapy could help counter empagliflozin-associated diabetic ketosis. In the study model, glycerol was used to support metabolic pathways that replenish intermediates of the tricarboxylic acid cycle, a central energy-producing system in cells.

The clinical implication is not that patients should self-treat ketosis with supplements. Instead, the study points to a mechanistic research direction: ketosis risk may involve more than simple carbohydrate restriction or glucose lowering, and future therapies could potentially target liver energy metabolism alongside insulin and fluid replacement. For now, standard DKA prevention and treatment remain the evidence-based approach.

How Should Patients Reduce SGLT2 Ketoacidosis Risk?

The FDA warns that SGLT2 inhibitors can be associated with ketoacidosis and advises clinicians to assess for ketoacidosis when symptoms suggest it, even if blood glucose is not markedly elevated. Warning signs can include nausea, vomiting, abdominal pain, unusual fatigue, shortness of breath and confusion. Patients taking insulin, those with type 1 diabetes physiology, people eating very low-carbohydrate diets and those with acute illness may need extra caution.

Before scheduled surgery, FDA labeling recommends temporarily stopping canagliflozin, dapagliflozin and empagliflozin at least three days before the procedure, and ertugliflozin at least four days before. Patients should not stop or restart these medicines without a clinician's plan, because SGLT2 inhibitors also have proven benefits for many people with type 2 diabetes, chronic kidney disease or heart failure.